Lindsay Lee
Primary Care · Greensboro, NCNPI 1366948556
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 254 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 18.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,153 and has fallen 51.9% since, to $555 in 2025. Among primary care clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 254 payments — averaging $15.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$715
- Novo Nordisk$666
- AbbVie$263
- Novartis$200
- Dexcom, Inc.$195
- Boehringer Ingelheim$176
- plus $2K from 33 others
What the payments were for
- Food & beverage$3,79898%
- Education$852%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 37 | $715 |
| Novo Nordisk | 79 | $666 |
| AbbVie | 14 | $263 |
| Novartis | 12 | $200 |
| Dexcom, Inc. | 6 | $195 |
| Boehringer Ingelheim | 11 | $176 |
| Amgen | 10 | $142 |
| Stemline Therapeutics Inc. | 1 | $136 |
| Astellas Pharma US Inc | 4 | $130 |
| Pfizer | 9 | $125 |
| Sanofi-aventis U.S. LLC | 6 | $121 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $90 |
| Otsuka America Pharmaceutical, Inc. | 4 | $85 |
| Xeris Pharmaceuticals, Inc. | 5 | $67 |
| Antares Pharma, Inc. | 4 | $67 |
| Lifescan, Inc. | 4 | $65 |
| Johnson & Johnson | 4 | $54 |
| GSK | 3 | $49 |
| Daiichi Sankyo Inc. | 2 | $48 |
| Mannkind Corporation | 4 | $48 |
| Merck | 3 | $41 |
| Amarin Pharma, Inc. | 3 | $34 |
| Cequr Corporation | 1 | $32 |
| Radius Health, Inc. | 2 | $30 |
| Abbott | 2 | $29 |
| E.r. Squibb & Sons, L.L.C. | 2 | $29 |
| Tolmar, Inc. | 2 | $28 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $27 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $20 |
| Irhythm Technologies, Inc. | 1 | $19 |
| Corcept Therapeutics | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Bayer | 1 | $17 |
| Madrigal Pharmaceuticals | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Shield Therapeutics Inc | 1 | $15 |
| Medtronic | 1 | $14 |
| Eisai Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Orserdu$136
- DEXCOM G7 GSS (161)$115
- MOUNJARO$110
How this compares
$3,883 in reported general payments places this provider in the 90th percentile of 236 primary care providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 26 | $23,886 |
| WegovySemaglutide | 15 | $19,785 |
| Repatha SureclickEvolocumab | 27 | $18,061 |
| OzempicSemaglutide | 17 | $16,763 |
| JardianceEmpagliflozin | 13 | $9,131 |
| Telmisartan | 30 | $1,259 |
| Escitalopram Oxalate | 69 | $1,042 |
| Pantoprazole Sodium | 51 | $694 |
| Olmesartan Medoxomil | 30 | $663 |
| Omeprazole | 28 | $648 |
| Rosuvastatin Calcium | 42 | $494 |
| Fluticasone Propionate | 15 | $494 |
| Hydralazine Hcl | 28 | $384 |
| Famotidine | 16 | $380 |
| Methocarbamol | 27 | $321 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskWegovy, Ozempic | $666 | $36,54932 claims |
| PfizerEliquis | $125 | $23,88626 claims |
| Boehringer IngelheimJardiance | $176 | $9,13113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 236 primary care providers in North Carolina.
Other primary care in Greensboro
- Elizabeth WalshGreensboro$7K
- Katie TateGreensboro$5K
- Sarah GrayGreensboro$4K
- Michelle EdwardsGreensboro$4K
- Alexandra ColeGreensboro$3K
- Anjanette ThompsonGreensboro$3K
- Emily MongeGreensboro$1K
- Jessica AllynRaleigh$21K
- Jennifer RogersWinston Salem$17K
- Elizabeth WaltersChapel Hill$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.